Listen to a Replay of the Q2 2021 Results Conference Call
Developing Innovative, Targeted Radiotherapeutics For Rare & Difficult-To-Treat Cancers
Plus Therapeutics, Inc. is investigating a novel radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in the U.S. National Institutes of Health-supported ReSPECT™ clinical trial for patients with recurrent glioblastoma – a rare, incurable, and fatal disease.
186RNL is designed to emit a Beta Ray to kill tumor cells while sparing surrounding healthy tissues and a Gamma Ray to visualize the therapy during and after administration to the patient.
Together, these 2 Rays may help healthcare providers take on this challenging type of brain cancer and give patients Hope.
Watch the Experts
Marc H. Hedrick, MD
Plus Therapeutics President & CEO
Inspiration for the company’s focus on helping patients with glioblastoma live longer.
Michael G. DeCuypere, MD PhD FAANS
Northwestern University Feinberg School of Medicine
A clinical trial plan for treating pediatric brain & spinal cord tumors with a poor prognosis.
Upcoming Events
Investor
September 13-15, Virtual
H.C. Wainwright 23rd Annual Global Investment Conference
Medical & Scientific
October 24-27, Chicago
American Society for Radiation Oncology (ASTRO) Annual Meeting
November 18-21, Boston
